{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:21:58Z","timestamp":1788009718754,"version":"build-2784847793"},"reference-count":30,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2019,1,17]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The signal is defined as \u201creported information on a possible causal relationship\nbetween an adverse event and a drug, of which the relationship is unknown or incompletely\ndocumented previously\u201d.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To detect novel adverse events of iloperidone by disproportionality analysis in FDA\ndatabase of Adverse Event Reporting System (FAERS) using Data Mining Algorithms (DMAs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology:<\/jats:title>\n                    <jats:p>The US FAERS database consists of 1028 iloperidone associated Drug Event\nCombinations (DECs) which were reported from 2010 Q1 to 2016 Q3. We consider DECs for\ndisproportionality analysis only if a minimum of ten reports are present in database for the given\nadverse event and which were not detected earlier (in clinical trials). Two data mining algorithms,\nnamely, Reporting Odds Ratio (ROR) and Information Component (IC) were applied retrospectively in\nthe aforementioned time period. A value of ROR-1.96SE&gt;1 and IC- 2SD&gt;0 were considered as the\nthreshold for positive signal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The mean age of the patients of iloperidone associated events was found to be 44years [95%\nCI: 36-51], nevertheless age was not mentioned in twenty-one reports. The data mining algorithms\nexhibited positive signal for akathisia (ROR-1.96SE=43.15, IC-2SD=2.99), dyskinesia (21.24, 3.06),\nperipheral oedema (6.67,1.08), priapism (425.7,9.09) and sexual dysfunction (26.6-1.5) upon analysis\nas those were well above the pre-set threshold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Iloperidone associated five potential signals were generated by data mining in the FDA\nAERS database. The result requires an integration of further clinical surveillance for the quantification\nand validation of possible risks for the adverse events reported of iloperidone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1574886313666181026100000","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T01:00:15Z","timestamp":1540774815000},"page":"21-26","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database"],"prefix":"10.2174","volume":"14","author":[{"given":"Viswam","family":"Subeesh","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bengaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eswaran","family":"Maheswari","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bengaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemendra","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Ramaiah Medical College, Bengaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Elsa","family":"Beulah","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bengaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Mary","family":"Swaroop","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bengaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4103\/0019-5545.43632","volume":"50","author":"Solanki R.K.","year":"2008","unstructured":"Solanki RK, Singh P, Midha A, Chugh K.  Schizophrenia: Impact on quality of life. \u200e.","journal-title":"Indian J Psychiatry"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2215-0366(15)00505-2","volume":"3","author":"Vigo D.","year":"2016","unstructured":"Vigo D, Thornicroft G, Atun R.  Estimating the true global burden of mental illness.","journal-title":"Lancet Psychiatry"},{"key":"ref=3","first-page":"469","volume":"140","author":"Thara R.","year":"2014","unstructured":"","journal-title":"Indian J Med Res"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/DDDT.S6443","volume":"4","author":"Caccia S.","year":"2010","unstructured":"Caccia S, Pasina L, Nobili A.  New atypical antipsychotics for schizophrenia: Iloperidone.","journal-title":"Drug Des Devel Ther"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/CE.S114094","volume":"11","author":"Tonin F.S.","year":"2016","unstructured":"Tonin FS, Wiens A, Fernandez-Llimos F, Pontarolo R.  Iloperidone in the treatment of schizophrenia: An evidence-based review of its place in therapy.","journal-title":"Core Evid"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4103\/0976-500X.99435","volume":"3","author":"Lahon K.","year":"2012","unstructured":"Lahon K, Shetty HM, Paramel A, Sharma G.  A retrospective study of extrapyramidal syndromes with second generation antipsychotics in the psychiatric unit of a tertiary care teaching hospital.","journal-title":"J Pharmacol Pharmacother"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1517\/14656566.7.13.1739","volume":"7","author":"Luft B.","year":"2006","unstructured":"Luft B, Taylor D.  A review of atypical antipsychotic drugs versus conventional medication in schizophrenia.","journal-title":"Expert Opin Pharmacother"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/0976-500X.114596","volume":"4","author":"Chadda R.K.","year":"2013","unstructured":"Chadda RK, Ramshankar P, Deb KS, Sood M.  Metabolic syndrome in schizophrenia: Differences between antipsychotic-na\u00efve and treated patients.","journal-title":"J Pharmacol Pharmacother"},{"key":"ref=9","first-page":"606","volume":"34","author":"Montes A.B.","year":"2009","unstructured":"Montes AB, Rey JA.  Iloperidone (Fanapt): An FDA-approved treatment option for schizophrenia.","journal-title":""},{"key":"ref=10","author":"","year":"","unstructured":".  WHO. Safety of Medicines - A Guide to Detecting and Reporting Adverse Drug Reactions - Why Health Professionals Need to Take Action 2002. Available from:"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2125.2003.01968.x","volume":"57","author":"Wilson A.M.","year":"2004","unstructured":"Wilson AM, Thabane L, Holbrook A.  Application of data mining techniques in pharmacovigilance.","journal-title":"Br J Clin Pharmacol"},{"key":"ref=12","author":"Poluzzi E","year":"","unstructured":"Poluzzi E, Raschi E, Piccinni C, De Ponti F."},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"Sakaeda T.","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y.  Data mining of the public version of the FDA Adverse Event Reporting System. \u200e.","journal-title":"Int J Med Sci"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00002018-200225060-00002","volume":"25","author":"Bate A.","year":"2002","unstructured":"Bate A, Lindquist M, Edwards IR, Orre R.  A data mining approach for signal detection and analysis.","journal-title":"Drug Saf"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clinthera.2011.03.006","volume":"33","author":"Crabtree B.L.","year":"2011","unstructured":"Crabtree BL, Montgomery J.  Iloperidone for the management of adults with schizophrenia.","journal-title":"Clin Ther"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/08998280.2010.11928615","volume":"23","author":"Sears E.","year":"2010","unstructured":"Sears E, Brooks S.  New drugs approved in 2009.","journal-title":"Proceedings (Baylor University Medical Center)"},{"key":"ref=17","first-page":"832","volume":"36","author":"Scarff J.R.","year":"2011","unstructured":"Scarff JR, Casey DA.  Newer oral atypical antipsychotic agents: A review.","journal-title":""},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1517\/17425255.2010.531259","volume":"6","author":"Citrome L.","year":"2010","unstructured":"Citrome L.  Iloperidone: Chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/YCO.0b013e32832a16da","volume":"22","author":"Kumar R.","year":"2009","unstructured":"Kumar R, Sachdev PS.  Akathisia and second-generation antipsychotic drugs.","journal-title":"Curr Opin Psychiatry"},{"key":"ref=20","first-page":"428","volume":"20","author":"Abbott C.","year":"2013","unstructured":"Abbott C, Jaramillo A, Wilcox C, Hamilton D.  Antipsychotic drug effects in schizophrenia: A review of longitudinal fmri investigations and neural interpretations.","journal-title":"Curr Med Chem"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1042\/CS20070018","volume":"112","author":"Zeng C.","year":"2007","unstructured":"Zeng C, Zhang M, Asico LD, Eisner GM, Jose PA.  The dopaminergic system in hypertension.","journal-title":"Clin Sci"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004850-200301000-00010","volume":"18","author":"Ng B.","year":"2003","unstructured":"Ng B, Postlethwaite A, Rollnik J.  Peripheral oedema in patients taking olanzapine. \u200e.","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/0253-7176.183089","volume":"38","author":"Umar M.U.","year":"2016","unstructured":"Umar MU, Abdullahi AT.  Self-limiting atypical antipsychotics-induced edema: Clinical cases and systematic review. \u200e.","journal-title":"Indian J Psychol Med"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"451.e5","DOI":"10.1016\/j.genhosppsych.2014.03.011","volume":"36","author":"Rodriguez-Cabezas L.A.","year":"2014","unstructured":"Rodriguez-Cabezas LA, Kong BY, Agarwal G.  Priapism associated with iloperidone: A case report.","journal-title":"Gen Hosp Psychiatry"},{"key":"ref=25","first-page":"198","volume":"12","author":"Hosseini S.H.","year":"2009","unstructured":"Hosseini SH, Polonowita AK.  Priapism associated with olanzapine.","journal-title":"PJBS"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5534\/wjmh.2012.30.3.153","volume":"30","author":"Park Y.W.","year":"2012","unstructured":"Park YW, Kim Y, Lee JH.  Antipsychotic-induced sexual dysfunction and its management.","journal-title":"World J Mens Health"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/0470842547.ch2","author":"B\u00e9gaud B.B.","year":"2002","unstructured":"B\u00e9gaud BB.","journal-title":"Dictionary of pharmacoepidemiology"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"Pariente A.","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N.  Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: The notoriety bias.","journal-title":"Drug Saf"},{"key":"ref=29","first-page":"1","author":"Weber J.C.P.","year":"1984","unstructured":"Weber JCP.  Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs.","journal-title":"Side-effects of anti-inflammatory drugs, advances in inflammation research"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-94-010-9772-7_2","author":"Weber J.C.P.","year":"1987","unstructured":"Weber JCP.  Epidemiology in the United Kingdom of adverse drug reactions from non-steroidal anti-inflammatory drugs.","journal-title":"Side-Effects of anti-inflammatory drugs: Part one clinical and epidemiological aspects"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/166658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T14:58:05Z","timestamp":1555858685000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/166658\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886313666181026100000","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}